Wenting Wu

6.0k total citations · 2 hit papers
23 papers, 4.0k citations indexed

About

Wenting Wu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Wenting Wu has authored 23 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 6 papers in Genetics. Recurrent topics in Wenting Wu's work include PARP inhibition in cancer therapy (10 papers), Advanced Breast Cancer Therapies (6 papers) and BRCA gene mutations in cancer (6 papers). Wenting Wu is often cited by papers focused on PARP inhibition in cancer therapy (10 papers), Advanced Breast Cancer Therapies (6 papers) and BRCA gene mutations in cancer (6 papers). Wenting Wu collaborates with scholars based in China, United States and Japan. Wenting Wu's co-authors include Carsten Goessl, Norikazu Masuda, Seock‐Ah Im, Binghe Xu, Mark E. Robson, Nadine Tung, Elżbieta Senkus, Pierfranco Conté, Susan M. Domchek and Sarah Runswick and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Wenting Wu

21 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 2.2k citations Mark E. Robson, Seock‐Ah Im et al. New England Journal of Medicine profile →
Olaparib for Metastatic Castration-Resistant Prostate Cancer

2020 1.4k citations Johann S. de Bono, Joaquı́n Mateo et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wenting Wu China	9	2.7k	1.8k	1.5k	1.0k	842	23	4.0k
Julia A. Beaver United States	39	2.7k 1.0×	1.5k 0.8×	1.1k 0.8×	1.1k 1.0×	207 0.2×	131	4.8k
Rashmi Chugh United States	39	2.1k 0.8×	2.5k 1.4×	1.5k 1.0×	547 0.5×	201 0.2×	172	4.9k
T. Delozier France	30	3.3k 1.3×	987 0.6×	568 0.4×	1.7k 1.6×	468 0.6×	92	4.3k
Maria Schwaederlé United States	28	1.5k 0.6×	1.1k 0.6×	1.0k 0.7×	1.7k 1.6×	235 0.3×	43	3.2k
Sophie Postel‐Vinay France	37	3.2k 1.2×	1.7k 1.0×	2.2k 1.5×	936 0.9×	181 0.2×	117	5.7k
Bruno V. Sinn Germany	27	1.6k 0.6×	523 0.3×	950 0.6×	1.2k 1.1×	121 0.1×	88	3.2k
Laura Orlando Italy	27	1.9k 0.7×	543 0.3×	946 0.6×	1.3k 1.3×	321 0.4×	92	2.9k
Laura M. Spring United States	27	2.2k 0.8×	1.3k 0.8×	835 0.6×	1.2k 1.2×	199 0.2×	132	3.4k
William Jacot France	34	2.7k 1.0×	1.4k 0.8×	1.1k 0.7×	1.2k 1.2×	274 0.3×	224	4.2k
Andrew H. Ko United States	35	3.8k 1.4×	963 0.5×	1.4k 1.0×	1.7k 1.6×	140 0.2×	150	4.9k

Countries citing papers authored by Wenting Wu

Since Specialization

Citations

This map shows the geographic impact of Wenting Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenting Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenting Wu more than expected).

Fields of papers citing papers by Wenting Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenting Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenting Wu. The network helps show where Wenting Wu may publish in the future.

Co-authorship network of co-authors of Wenting Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Wenting Wu. A scholar is included among the top collaborators of Wenting Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenting Wu. Wenting Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Wang, Xu, Zhizhong Xiao, Wenting Wu, et al.. (2025). Clinical confirmation of an infection with Echinococcus multilocularis (Mongolian genotype): first case report of human alveolar echinococcosis in Inner Mongolia, China. Infectious Diseases of Poverty. 14(1). 74–74.

2.

Hansen, Aaron R., Stephan Probst, Jean‐Mathieu Beauregard, et al.. (2025). Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial. Frontiers in Oncology. 14. 1483953–1483953. 1 indexed citations

3.

Wu, Wenting & Liang Zhao. (2025). Building Evaluation Model for Low-Carbon Transformation of Power Systems Based on Ecological Modernization Theory. 830–835.

4.

Yang, Shun‐Mao, et al.. (2024). Augmented fluoroscopy-guided dye localization for small pulmonary nodules in hybrid operating room: intrathoracic stamping versus transbronchial marking. International Journal of Computer Assisted Radiology and Surgery. 19(11). 2203–2213. 1 indexed citations

5.

Wu, Wenting, et al.. (2024). The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-alpha inhibitors: a systematic review and meta-analysis. Clinical and Experimental Dermatology. 50(5). 968–980. 1 indexed citations

6.

Wu, Wenting, Dongzhi Wang, & Dongyan Zhang. (2023). Aridity index and quantile regression influences on the maximum size-density relationship for coniferous and broad-leaved mixed forests. Forest Ecology and Management. 543. 121148–121148. 4 indexed citations

7.

Wang, Xu, et al.. (2022). The First Detection of <i>Echinococcus</i> <i>Granulosus</i> DNA in Residents’ Hands, Dogs’ Hair, and Soil in Highly Endemic Region of Echinococcosis — Naqu City, Xizang Autonomous Region, China, 2020. China CDC Weekly. 4(44). 982–985. 2 indexed citations

8.

Chen, Chung‐Yu, Wenting Wu, Yaling Wang, & Kuang‐Ming Liao. (2021). Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease. Frontiers in Pharmacology. 11. 613761–613761. 6 indexed citations

9.

Bono, Johann S. de, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 382(22). 2091–2102. 1397 indexed citations breakdown →

10.

Im, Seock‐Ah, Binghe Xu, Wei Li, et al.. (2020). Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports. 10(1). 8753–8753. 25 indexed citations

11.

Wu, Wenting & Chung‐Yu Chen. (2020). Protective Effect of Statins on Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Patients: A Nationwide Retrospective, Matched Cohort Study. Scientific Reports. 10(1). 3104–3104. 12 indexed citations

12.

Tung, Nadine, Seock‐Ah Im, Elżbieta Senkus, et al.. (2018). Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.. Journal of Clinical Oncology. 36(15_suppl). 1052–1052. 9 indexed citations

13.

Robson, Mark E., Seock‐Ah Im, Elżbieta Senkus, et al.. (2018). Abstract CT038: OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Cancer Research. 78(13_Supplement). CT038–CT038. 3 indexed citations

14.

Xie, Zhiqiang, Junzhou Fu, Wenhu Liu, et al.. (2018). [Correlation between Ameliorated Kawashima Itch Scale and Visual Analogue Scale].. PubMed. 40(4). 539–542. 1 indexed citations

15.

Robson, Mark E., Seock‐Ah Im, Elżbieta Senkus, et al.. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine. 377(6). 523–533. 2156 indexed citations breakdown →

16.

Robson, Mark E., Seock‐Ah Im, Elżbieta Senkus, et al.. (2017). OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).. Journal of Clinical Oncology. 35(18_suppl). LBA4–LBA4. 24 indexed citations

17.

Robson, Mark E., Seock‐Ah Im, Elżbieta Senkus, et al.. (2017). OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).. Journal of Clinical Oncology. 35(15_suppl). LBA4–LBA4. 7 indexed citations

18.

Huang, Yongsheng, Wenting Wu, Meng Nie, Chuang Li, & Lin Wang. (2016). SMAD7 polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies. 3 indexed citations

19.

Huang, Yongsheng, Wenting Wu, Meng Nie, Chuang Li, & Lin Wang. (2016). SMAD7 polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies. Oncotarget. 7(46). 75561–75570. 15 indexed citations

20.

Tutt, Andrew, Bella Kaufman, Richard D. Gelber, et al.. (2015). OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).. Journal of Clinical Oncology. 33(15_suppl). TPS1109–TPS1109. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact